Details for Patent: 10,555,939
✉ Email this page to a colleague
Which drugs does patent 10,555,939 protect, and when does it expire?
Patent 10,555,939 protects POMALYST and is included in one NDA.
Protection for POMALYST has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.
This patent has fifty patent family members in thirty-three countries.
Summary for Patent: 10,555,939
Title: | Formulations of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione |
Abstract: | Pharmaceutical compositions and single unit dosage forms of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione, or a pharmaceutically acceptable stereoisomer, prodrug, salt, solvate, hydrate, or clathrate, are provided herein. Also provided are methods of treating, managing, or preventing various disorders, such as cancer or an inflammatory disease. |
Inventor(s): | Tutino; Anthony J. (New Providence, NJ), Kelly; Michael T. (Lake Hopatcong, NJ) |
Assignee: | Celgene Corporation (Summit, NJ) |
Application Number: | 15/976,808 |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 10,555,939 |
Patent Claim Types: see list of patent claims | Composition; Dosage form; |
Drugs Protected by US Patent 10,555,939
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Bristol | POMALYST | pomalidomide | CAPSULE;ORAL | 204026-001 | Feb 8, 2013 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | ||||
Bristol | POMALYST | pomalidomide | CAPSULE;ORAL | 204026-002 | Feb 8, 2013 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | ||||
Bristol | POMALYST | pomalidomide | CAPSULE;ORAL | 204026-003 | Feb 8, 2013 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | ||||
Bristol | POMALYST | pomalidomide | CAPSULE;ORAL | 204026-004 | Feb 8, 2013 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 10,555,939
Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
---|---|---|---|---|---|
Australia | 2010249615 | ⤷ Try a Trial | |||
Brazil | PI1007855 | ⤷ Try a Trial | |||
Canada | 2752550 | ⤷ Try a Trial | |||
Chile | 2011001969 | ⤷ Try a Trial | |||
China | 102333525 | ⤷ Try a Trial | |||
China | 105640918 | ⤷ Try a Trial | |||
>Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |